We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Protective effect of rosuvastatin pretreatment against acute myocardial injury by regulating Nrf2, Bcl-2/Bax, iNOS, and TNF-α expressions affecting oxidative/nitrosative stress and inflammation.
- Authors
Sultan, Faheem; Kaur, Rajdeep; Tarfain, Najeeb U; Mir, Arshad H; Dumka, Vinod K; Sharma, Suresh K; Singh Saini, Simrat P
- Abstract
Cardiovascular disorders are the leading cause of death globally. Rosuvastatin is a member of statins (inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase) with many pleiotropic properties. This study investigated cardioprotective effects of rosuvastatin in isoprenaline-induced myocardial injury. Male rats were given rosuvastatin (1, 5, or 10 mg/kg, oral) daily for 1 week and on seventh and eighth day isoprenaline (150 mg/kg, subcutaneous) was given to induce cardiac injury. On ninth day, rats were euthanized and different samples were harvested for analysis. Isoprenaline administration resulted in increased cardiac mass, increased cardiac injury marker levels (cTnI, CK-MB, ALT, and AST), increased lipid/protein oxidation, and increased cardiac nitrite levels. It also decreased superoxide dismutase, CAT, GST, and glutathione reductase activities, and total antioxidant activity. Isoprenaline also increased TNF-α and IL-6 levels. Decreased mRNA expression of Nrf2 and Bcl-2 along with increased mRNA expression of Bax, eNOS and iNOS genes was observed in isoprenaline treated animals. Histopathological evaluations of rosuvastatin pre-treated groups showed reduction of myocardial necrosis. Pretreatment with rosuvastatin (5 and 10 mg/kg) reduced many of these pathological changes. The current study showed that rosuvastatin significantly reduces myocardial injury induced by isoprenaline.
- Subjects
INTERLEUKINS; BIOLOGICAL models; CARDIOTOXICITY; ROSUVASTATIN; NUCLEAR factor E2 related factor; ANIMAL experimentation; INFLAMMATION; MYOCARDIAL injury; RATS; OXIDATIVE stress; TUMOR necrosis factors; PHARMACODYNAMICS
- Publication
Human & Experimental Toxicology, 2022, Vol 41, p1
- ISSN
0960-3271
- Publication type
Article
- DOI
10.1177/09603271211066065